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A large number of genes are altered in cancer cells.
Often, reversal or inhibition of just one of these
alterations leads to death of the cancer cells.
Technological advances in multiple areas are
necessary to potentiate clinical translation of these
findings. In a recent article, Brock and colleagues
reported that overexpressed HOXA1 is a critical event
in tumor progression in a mouse mammary tumor
model. They developed HOXA1-small interfering RNA
nanoparticles and achieved effective therapeutic doses
by delivering them intraductally through the nipple to
the site of the tumor and at the same time
circumvented the systemic immune response. This study
strengthens the concept of targeting overexpressed
genes by using small interfering RNA and bypassing
systemic immunity through local intraductal delivery.resulted in more acinar (hollow) lumen formation of cellsIntroduction
Whole genomic analysis has identified a large number of
genes that are overexpressed in cancer cells; reversal of
mechanisms leading to overexpression often leads to death
of the cancer cells. Selective gene inhibition by the small
interfering RNA (siRNA) strategy has fired the imagi-
nation of drug developers. This excitement is based on the
ability of siRNAs to enter the cell and interfere with virtu-
ally every targetable transcript that codes for intracellular
proteins, and even non-coding RNA. However, keeping
the siRNA intact during systemic transport, preventing an
immune response against it, and getting it to its target
organ at levels needed for successful therapy have pre-
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In the article by Brock and colleagues [1], the authors bring
two concepts together to overcome obstacles in siRNA
therapy. First, using tissue-specific microarray analysis in a
transgenic mammary tumor model, they constructed a gene
regulatory network to identify key promoters active during
tumor formation. Among other candidates, the transcrip-
tion factor HOXA1 was found to be significantly over-
expressed during cancer progression. Second, using lipidoid
nanoparticles as a carrier, they delivered siRNA targeting
HOXA1 to mouse mammary glands via intraductal (i.duc)
injection, thereby ensuring successful targeting and bypass-
ing systemic immune response. The siRNA-conjugated
nanoparticles, when injected through the nipples of C3 (1)-
SV40Tag transgenic mice, significantly reduced the inci-
dence of spontaneous mammary tumors.
They also observed that siRNA-mediated depletion of
HOXA1 in two other mouse mammary tumor cell lines
grown in matrigel. Findings in this cell culture model,
commonly used to mimic preneoplastic ductal carcinoma
in situ (DCIS) in humans, suggested that HOXA1 may be
a key mediator in the early stages of breast tumor forma-
tion. Oncomine database analysis strengthened their hy-
pothesis since HOXA1 was found to be overexpressed in
human breast cancers. To silence HOXA1 in mammary
tissues in vivo, they injected virgin C3 (1)-SV40Tag mice
with nanoparticle-siRNA complex bi-weekly through the
nipple for 9 weeks, starting when the mice were 12 weeks
of age. Whereas all the control mice developed tumors,
75% of HOXA1 siRNA-nanoparticle-treated mice remained
tumor-free at 21 weeks. Most noteworthy is that i.duc
treatment with siRNA in the transgenic mice did not
cause local tissue damage or any obvious systemic side
effect. When performed multiple times, i.duc injection
can cause leakage of material into normal tissue. There-
fore, the lack of deleterious consequences is an important
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Advances in next-generation sequencing and bioinfor-
matics are continuing to inform us of the steps from
cancer initiation to progression. Among transcripts that
are differentially expressed in breast cancer, those that are
highly expressed in cancer cells are theoretically targetable
by siRNA. The hopes pinned on siRNAs stem from the
fact that they are more specific than other cancer therap-
ies; indeed, they can even discriminate between species
that have single-nucleotide differences [2,3]. As a result,
phenotypes caused by gain-of-function mutations and
gene translocations are also potentially reversible with
siRNA-based therapy.
I.duc siRNA therapy would benefit women with atypical
ductal hyperplasia or DCIS and women at high risk of
developing breast cancer because of a family history of
mutated BRCA1/2 or other familial breast cancer genes.
Could the preneoplastic lesions present in the entire
ductal tree be accessed for treatment through the i.duc
route? As early as 2002, Sivaraman and colleagues [4]
demonstrated the feasibility of accessing rat ducts through
the nipple for treatment. We used i.duc injection of slow-
release liposomal doxorubicin (Doxil) to successfully elim-
inate preneoplasias in both the HER/2 neu transgenic
mouse and carcinogen-induced rat mammary tumor
models [5] and to delay carcinoma formation by using
curcumin [6]. We [7] and others [8] also demonstrated
the feasibility and safety of the i.duc approach by using
Doxil in women undergoing mastectomy for breast can-
cer. However, the use of DNA-synthesis-targeted drugs
carries the risk of iatrogenic cancer in the distant future.
Although there are clear species differences between
humans and mice, laboratory-bred female mice developed
cancer when doxorubicin [9] or fluorouracil (our unpub-
lished findings) was injected intraductally, with a latency
of nearly a year. On the other hand, agents such as siRNA
and similar biologic therapies may not carry these risks.
The article by Brock and colleagues [1] has firmly
established the feasibility of using HOXA1 siRNA-
nanoparticles as an effective cancer preventive/therapeutic
agent and their delivery into the ducts through the nipple
as a means of treating mammary preneoplasias in the
preclinical setting. However, as pointed out by the authors,
this study does not offer evidence that HOXA1 is a candi-
date gene that is overexpressed in DCIS [10] or that
HOXA1 overexpression in DCIS predicts progression to
invasive cancer [11]. Several laboratories, including ours,
are engaged in comparative genomic analysis of DCIS that
does, or does not, progress to invasive cancer; these stud-
ies will likely shed light on the importance of HOXA1 in
the progression of DCIS to invasive cancer in the near
future. Secondly, the number of i.duc injections that were
performed to observe a reduction in tumor incidence
presents a barrier to clinical translation. Although theintactness of the ducts is retained for up to four injections,
our experience shows that the likelihood of collapsing
ducts is high in mice if injections continued multiple
times. Pharmacokinetic studies in the future could offer
indications of longer-lasting effects of the siRNA-
nanoparticles and thus the need for less frequent injec-
tions. This will ensure feasibility of clinical trials testing
this concept. Despite these considerations for future trans-
lation of the work to the clinic, the work has undoubtedly
demonstrated the power of discovery of overexpressed
genes that are critical for development of the mammary
tumor, the development of the siRNA strategy, and suc-
cessful implementation of the approach by using intraduc-
tal administration to circumvent the immune system and
to directly deliver effective doses of the agent at the
desired site of the tumor, while sparing the other organs.
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